GB202213308D0 - combinations and pharmaceutical compositions comprising a P13K/mTOR pathway inhibiting compound - Google Patents
combinations and pharmaceutical compositions comprising a P13K/mTOR pathway inhibiting compoundInfo
- Publication number
- GB202213308D0 GB202213308D0 GBGB2213308.6A GB202213308A GB202213308D0 GB 202213308 D0 GB202213308 D0 GB 202213308D0 GB 202213308 A GB202213308 A GB 202213308A GB 202213308 D0 GB202213308 D0 GB 202213308D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- combinations
- pharmaceutical compositions
- inhibiting compound
- mtor pathway
- pathway inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 title 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000037361 pathway Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2213308.6A GB202213308D0 (en) | 2022-09-12 | 2022-09-12 | combinations and pharmaceutical compositions comprising a P13K/mTOR pathway inhibiting compound |
| PCT/GB2023/052322 WO2024056995A1 (en) | 2022-09-12 | 2023-09-08 | Combinations and pharmaceutical compositions comprising a pi3k/akt/mtor pathway inhibiting compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2213308.6A GB202213308D0 (en) | 2022-09-12 | 2022-09-12 | combinations and pharmaceutical compositions comprising a P13K/mTOR pathway inhibiting compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202213308D0 true GB202213308D0 (en) | 2022-10-26 |
Family
ID=83945332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2213308.6A Ceased GB202213308D0 (en) | 2022-09-12 | 2022-09-12 | combinations and pharmaceutical compositions comprising a P13K/mTOR pathway inhibiting compound |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB202213308D0 (en) |
| WO (1) | WO2024056995A1 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106581009A (en) * | 2015-10-14 | 2017-04-26 | 南京中医药大学 | Composition having synergistic antitumor effect |
-
2022
- 2022-09-12 GB GBGB2213308.6A patent/GB202213308D0/en not_active Ceased
-
2023
- 2023-09-08 WO PCT/GB2023/052322 patent/WO2024056995A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024056995A1 (en) | 2024-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0621957D0 (en) | Inhaler devices and bespoke pharmaceutical compositions | |
| IL197295A0 (en) | Pharmaceutical composition comprising a plurality of mini-tablets comprising a factor xa inhibitor | |
| GB202019241D0 (en) | Pharmaceutical composition | |
| IL304525A (en) | Pharmaceutical composition comprising a diphenylpyrazine derivative | |
| GB202213308D0 (en) | combinations and pharmaceutical compositions comprising a P13K/mTOR pathway inhibiting compound | |
| EP4132511A4 (en) | Pharmaceutical compositions comprising meloxicam | |
| EP4135699A4 (en) | Pharmaceutical compositions | |
| EP4142715A4 (en) | Novel pharmaceutical formulation for c-met inhibitor | |
| GB202313738D0 (en) | Pharmaceutical compositions | |
| GB202312055D0 (en) | Pharmaceutical compositions | |
| GB202217146D0 (en) | New pharmaceutical compositions | |
| GB202217150D0 (en) | New pharmaceutical compositions | |
| IL300090A (en) | Pharmaceutical compositions comprising venglustat | |
| IL307928A (en) | Pharmaceutical compositions comprising picroside | |
| GB202102575D0 (en) | Fixed-dose pharmaceutical compositions | |
| EP4171529A4 (en) | Topical pharmaceutical compositions | |
| EP4104825A4 (en) | Pharmaceutical composition for inhibiting inflammatory response comprising hydroxyurea | |
| GB202213122D0 (en) | Curcumin compound composition | |
| GB202019335D0 (en) | Pharmaceutical compositions | |
| GB202013701D0 (en) | Pharmaceutical compositions | |
| GB202403415D0 (en) | Pharmaceutical composition | |
| GB202316245D0 (en) | Rapamycin-containing pharmaceutical composition | |
| GB202204335D0 (en) | Non-antibiotic antimicrobial compositions | |
| GB202218929D0 (en) | New pharmaceutical composition | |
| GB202218958D0 (en) | New pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |